Abstract
Colorectal cancer develops as the result of the progressive accumulation of genetic and epigenetic alterations that lead to the transformation of normal colonic epithelium to colon adenocarcinoma. The fact that colon cancer develops over 10–15 years and progresses through parallel histologic and molecular changes has permitted the study of its molecular pathology in more detail than other cancer types. Consequently, the specific nature of many of these cancer-associated genetic alterations has been determined over the last 15 years. The subsequent effect of these alterations on the cell and molecular biology of the cancer cells in which they occur has also begun to be revealed over the last decade. From the analysis of the molecular genesis of colon cancer, three key themes concerning the molecular pathogenesis of cancer have been established. The first is that cancer emerges via a multistep progression at both the molecular and the morphologic levels (1). The second is that loss of genomic stability is a key molecular and pathophysiologic step in cancer formation (2). The third is that hereditary cancer syndromes frequently correspond to germline forms of key genetic defects whose somatic occurrences drive the emergence of sporadic colon cancers (3).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fearon, E. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759–767.
Lengauer, C., Kinzler, K., and Vogelstein, B. (1998) Genetic instabilities in human cancers. Nature 396, 643–649.
Kinzler, K. and Vogelstein, B. (1996) Lessons from hereditary colorectal cancer. Cell 87, 159–170.
Aaltonen, L., Peltomaki, P., Mecklin, J.-P., et al. (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 54, 1645–1648.
Grady, W., Rajput, A., Myeroff, L., et al. (1998) Mutation of the type II transforming growth factor-b receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 58, 3101–3104.
Jacoby, R., Marshall, D., Kailas, S., Schlack, S., Harms, B., and Love, R. (1995) Genetic instability associated with adenoma to carcinoma progression in hereditary nonpolyposis colon cancer. Gastroenterology 109, 73–82.
Bomme, L., Bardi, G., Pandis, N., Fenger, C., Kronborg, O., and Heim, S. (1998) Cytogenetic analysis of colorectal adenomas: karyotypic comparisons of synchronous tumors. Cancer Genet. Cytogene. 106, 66–71.
Ried, T., Heselmeyer-Haddad, K., Blegen, H., Schrock, E., and Auer, G. (1999) Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 25, 195–204.
Rooney, P., Murray, G., Stevenson, D., Haites, N., Cassidy, J., and McLeod, H. (1999) Comparative genomic hybridization and chromosomal instability in solid tumors. Br. J. Cancer 80, 862–873.
Shih, I. M., Zhou, W., Goodman, S. N., Lengauer, C., Kinzler, K. W., and Vogelstein, B. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res. 61, 818–822.
Herrera, L., Kakati, S., Gibas, L., Pietrzak, E., and Sandberg, A. A. Gardner (1986) syndrome in a man with an interstitial deletion of 5q. Am. J. Med. Genet. 25, 473–476.
Groden, J., Thliveris, A., Samowitz, W., et al. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589–600.
Nishisho, I., Nakamura, Y., Miyoshi, Y., et al. (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253, 665–669.
Mori, T., Nagase, H., Horii, A., et al. (1994) Germ-line and somatic mutations of the APC gene in patients with Turcot syndrome and analysis of APC mutations in brain tumors. Genes Chromo. Cancer 9, 168–172.
Spirio, L., Otterud, B., Stauffer, D., et al. (1992) Linkage of a variant or attenuated form of adenomatous polyposis coli to the adenomatous polyposis coli (APC) locus. Am. J. Hum. Genet. 51, 92–100.
Soravia, C., Berk, T., Madlensky, L., et al. (1998) Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am. J. Hum. Genet. 62, 1290–1301.
Foulkes, W. D. (1995) A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. Q. J. Med. 88, 853–863.
Vogelstein, B., Fearon, E. R., Hamilton, S. R., et al. (1988) Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532.
Miyaki, M., Konishi, M., Kikuchi-Yanoshita, R., et al. (1994) Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res. 54, 3011–3020.
Chung, D. (2000) The genetic basis of colorectal cancer:insights into critical pathways of tumorigenesis. Gastroenterology 119, 854–865.
Powell, S. M., Zilz, N., Beazer-Barclay, Y., et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359, 235–237.
Miyoshi, Y., Nagase, H., Ando, H., et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum. Mol. Genet. 1, 229–233.
Jen, J., Powell, S. M., Papadopoulos, N., et al. (1994) Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54, 5523–5526.
Smith, A. J., Stern, H. S., Penner, M., et al. (1994) Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 54, 5527–5530.
Su, L. K., Vogelstein, B., and Kinzler, K. W. (1993) Association of the APC tumor suppressor protein with catenins. Science 262, 1734–1737.
Rubinfeld, B., Souza, B., Albert, I., et al. (1993) Association of the APC gene product with beta-catenin. Science 262, 1731–1734.
Behrens, J., Jerchow, B. A., Wurtele, M., et al. (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280, 596–599.
Powell, S. M., Petersen, G. M., Krush, A. J., et al. (1993) Molecular diagnosis of familial adenomatous polyposis [see comments]. N. Engl. J. Med. 329, 1982–1987.
Spirio, L. N., Samowitz, W., Robertson, J., et al. (1998) Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat. Genet. 20, 385–388.
He, T. C., Sparks, A. B., Rago, C., et al. (1998) Identification of c-MYC as a target of the APC pathway [see comments]. Science 281, 1509–1512.
Tetsu, O. and McCormick, F. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422–426.
Crawford, H. C., Fingleton, B. M., Rudolph-Owen, L. A., et al. (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18, 2883–2891.
He, T. C., Chan, T. A., Vogelstein, B., and Kinzler, K. W. (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335–345.
Mann, B., Gelos, M., Siedow, A., et al. (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. U S A 96, 1603–1608.
Pennica, D., Swanson, et al. (1998) WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc. Natl. Acad. Sci. U S A 95, 14717–14722.
Sparks, A. B., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58, 1130–1134.
Kitaeva, M., Grogan, L., Williams, J., et al. (1997) Mutations in b-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res. 57, 4478–4481.
Harada, N., Tamai, Y., Ishikawa, T., et al. (1999) Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 18, 5931–5942.
Olschwang, S., Tiret, A., Laurent-Puig, P., Muleris, M., Parc, R., and Thomas, G. (1993) Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell 75, 959–968.
Caspari, R., Olschwang, S., Friedl, W., et al. (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum. Mol. Genet. 4, 337–340.
Spirio, L., Olschwang, S., Groden, J., et al. (1993) Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75, 951–957.
Gardner, R. J., Kool, D., Edkins, E., et al. (1997) The clinical correlates of a 3′ truncating mutation (codons 1982–1983) in the adenomatous polyposis coli gene. Gastroenterology 113, 326–331.
Laken, S. J., Petersen, G. M., Gruber, S. B., et al. (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat. Genet. 17, 79–83.
Lothe, R. A., Hektoen, M., Johnsen, H., et al. (1998) The APC gene I1307K variant is rare in Norwegian patients with familial and sporadic colorectal or breast cancer. Cancer Res. 58, 2923–2924.
Hulsken, J., Birchmeier, W., and Behrens, J. (1994) E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J. Cell Biol. 127, 2061–2069.
Aberle, H., Butz, S., Stappert, J., Weissig, H., Kemler, R., and Hoschuetzky, H. (1994) Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J. Cell Sci. 107, 3655–3663.
Moon, R. T., Brown, J. D., Yang-Snyder, J. A., and Miller, J. R. (1997) Structurally related receptors and antagonists compete for secreted Wnt ligands. Cell 88, 725–728.
Rubinfeld, B., Albert, I., Porfiri, E., Munemitsu, S., and Polakis, P. (1997) Loss of betacatenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res. 57, 4624–4630.
Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B., and Polakis, P. (1995) Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl. Acad. Sci. USA 92, 3046–3050.
Munemitsu, S., Albert, I., Rubinfeld, B., and Polakis, P. (1996) Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein. Mol. Cell Biol. 16, 4088–4094.
Morin, P. J., Sparks, A. B., Korinek, V., et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC [see comments]. Science 275, 1787–1790.
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines [see comments]. Science 275, 1790–1792.
Shtutman, M., Zhurinsky, J., Simcha, I., et al. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96, 5522–5527.
Park, W. S., Oh, R. R., Park, J. Y., et al. (1999) Frequent somatic mutations of the betacatenin gene in intestinal-type gastric cancer. Cancer Res. 59, 4257–4260.
Caca, K., Kolligs, F. T., Ji, X., et al. (1999) Beta-and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ. 10, 369–376.
Kawanishi, J., Kato, J., Sasaki, K., Fujii, S., Watanabe, N., and Niitsu, Y. (1995) Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol. Cell Biol. 15, 1175–1181.
Luber, B., Candidus, S., Handschuh, G., et al. (2000) Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate [In Process Citation]. Cell Adhes. Commun. 7, 391–408.
Samowitz, W. S., Powers, M. D., Spirio, L. N., Nollet, F., van Roy, F., and Slattery, M. L. (1999) Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 59, 1442–1444.
Duval, A., Gayet, J., Zhou, X. P., Iacopetta, B., Thomas, G., and Hamelin, R. (1999) Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res. 59, 4213–4215.
Ishitani, T., Ninomiya-Tsuji, J., Nagai, S., et al. (1999) The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 399, 798–802.
Seeling, J. M., Miller, J. R., Gil, R., Moon, R. T., White, R., and Virshup, D. M. (1999) Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 283, 2089–2091.
Wang, S. S., Esplin, E. D., Li, J. L., et al. (1998) Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282, 284–287.
Boland, C., Thibodeau, S., Hamilton, S., et al. (1998) National Cancer Institute workshop on microsatellite instability for cancer detection and familial predispostion:development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248–5257.
Wu, Y., Berends, M. J., Post, J. G., et al. (2001) Germline mutations of exo1 gene in patients with hereditary nonpolyposis colorectal cancer (hnpcc) and atypical hnpcc forms. Gastroenterology 120, 1580–1587.
Marra, G. and Boland, C. (1995) Hereditary nonpolyposis colorectal cancer∶the syndrome, the genes, and historical perspective, J. Natl. Cancer Inst. 87, 1114–1125.
Wijnen, J. T., Vasen, H. F., Khan, P. M., et al. (1998) Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N. Engl. J. Med. 339, 511–518.
Liu, B., Parsons, R., Papadopoulos, N., et al. (1996) Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients [see comments]. Nat. Med. 2, 169–174.
Hemminki, A., Peltomaki, P., Mecklin, J. P., et al. (1994) Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat. Genet. 8, 405–410.
Peltomaki, P. and Vasen, H. F. (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113, 1146–1158.
Yan, H., Papadopoulos, N., Marra, G., et al. (2000) Conversion of diploidy to haploidy. Nature 403, 723–724.
Liu, B., Nicolaides, N., Markowitz, S., et al. (1995) Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genet. 9, 48–53.
Kane, M., Loda, M., Gaida, G., et al. (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808–811.
Veigl, M., Kasturi, L., Olechnowicz, J., et al. (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. 95, 8698–8702.
Jiricny, J. (1998) Replication errors: cha(lle)nging the genome. EMBO J. 17, 6427–6436.
Kolodner, R. D. and Marsischky, G. T. (1999) Eukaryotic DNA mismatch repair. Curr. Opin. Genet. Dev. 9, 89–96.
Eshleman, J., Lang, E., Bowerfind, G., et al. (1995) Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 10, 33–37.
Yamamoto, H., Sawai, H., Weber, T., Rodriguez-Bigas, M., and Perucho, M. (1998) Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res. 58, 997–1003.
Markowitz, S., Wang, J., Myeroff, L., et al. (1995) Inactivation of the type II TGF-b receptor in colon cancer cells with microsatellite instability. Science 268, 1336–1338.
Schwartz, S., Yamamoto, H., Navarro, M., Maestro, M., Reventos, J., and Perucho, M. (1999) Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 59, 2995–3002.
Ikeda, M., Orimo, H., Moriyama, H., et al. (1998) Close correlation between mutations of E2F4 and hMSH3 genes in colorectal cancers with microsatellite instability. Cancer Res. 58, 594–598.
Piao, Z., Fang, W., Malkhosyan, S., et al. (2000) Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability [In Process Citation]. Cancer Res. 60, 4701–4704.
Wicking, C., Simms, L. A., Evans, T., et al. (1998) CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer. Oncogene 17, 657–659.
Huang, J., Papadopoulos, N., McKinley, A., et al. (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc. Natl. Acad. Sci. USA 93, 9049–9054.
Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., et al. (1996) Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 111, 307–317.
Miyaki, M., Iijima, T., Kimura, J., et al. (1999) Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res. 59, 4506–4509.
Fujiwara, T., Stolker, J. M., Watanabe, T., et al. (1998) Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am. J. Pathol. 153, 1063–1078.
Eshleman, J., Casey, G., Kochera, M., et al. (1998) Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene 17, 719–725.
Olschwang, S., Hamelin, R., Laurent-Puig, P., et al. (1997) Alternative genetic pathways in colorectal carcinogenesis. Proc. Natl. Acad. Sci. USA 94, 12122–12127.
Lynch, H. T. and de la Chapelle, A. (1999) Genetic susceptibility to non-polyposis colorectal cancer. J. Med. Genet. 36, 801–818.
Watson, P., Lin, K. M., Rodriguez-Bigas, M. A., et al. (1998) Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members [see comments]. Cancer 83, 259–266.
Aarnio, M., Mecklin, J. P., Aaltonen, L. A., Nystrom-Lahti, M., and Jarvinen, H. J. (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer 64, 430–433.
Miyaki, M., Konishi, M., Tanaka, K., et al. (1997) Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer [letter]. Nat. Genet. 17, 271–272.
Akiyama, Y., Sato, H., Yamada, T., et al. (1997) Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 57, 3920–3923.
Herman, J., Umar, A., Polyak, K., et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 95, 6870–6875.
Baylin, S. B. and Herman, J. G. (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16, 168–174.
Jones, P. and Laird, P. (1999) Cancer epigenetics comes of age. Nature Genet. 21, 163–167.
Deng, G., Chen, A., Hong, J., Chae, H., and Kim, Y. (1999) Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 59, 2029–2033.
Grady, W. M., Willis, J., Guilford, P. J., et al. (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer [In Process Citation] Nat. Genet. 26, 16–17.
Herman, J. G., Merlo, A., Mao, L., et al. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525–4530.
Toyota, M., Ho, C., Ahuja, N., et al. (1999) Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 59, 2307–2312.
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., and Issa, J. P. (1999) CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96, 8681–8686.
Lu, S. L., Kawabata, M., Imamura, T., et al. (1998) HNPCC associated with germline mutation in the TGF-beta type II receptor gene [letter]. Nat. Genet. 19, 17–18.
Markowitz, S. and Roberts, A. (1996) Tumor supressor activity of the TGF-b pathway in human cancers. Cytokine Growth Factor Rev. 7, 93–102.
Fynan, T. M. and Reiss, M. (1993) Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit. Rev. Oncog. 4, 493–540.
Massague, J. (1996) TGF-b signaling: receptors, transducers, and mad proteins. Cell 85, 947–950.
Wrana, J. and Pawson, T. (1997) Signal transduction. Mad about SMADs [news; comment]. Nature 388, 28–29.
Luo, K., Stroschein, S. L., Wang, W., et al. (1999) The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev. 13, 2196–2206.
Hua, X., Liu, X., Ansari, D. O., and Lodish, H. F. (1998) Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. 12, 3084–3095.
Geng, Y. and Weinberg, R. A. (1993) Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc. Natl. Acad. Sci. USA 90, 10315–10319.
Howe, P. H., Draetta, G., and Leof, E. B. (1991) Transforming growth factor beta 1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest. Mol. Cell Biol. 11, 1185–1194.
Ewen, M. E., Sluss, H. K., Whitehouse, L. L., and Livingston, D. M. (1993) TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 74, 1009–1020.
Alexandrow, M. and Moses, H. (1995) Transforming growth factor b and cell cycle regulation. Cancer Res. 55, 1452–1457.
Hannon, G. and Beach, D. (1994) p15INK4B is a potential effector of TGF-b-induced cell cycle arrest. Nature 371, 257–261.
Moses, H., Yang, E., and Pietonpol, J. (1990) TGF-b stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63, 245–247.
Keeton, M. R., Curriden, S. A., van Zonneveld, A. J., and Loskutoff, D. J. (1991) Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J. Biol. Chem. 266, 23048–23052.
Zhao, Y. (1999) Transforming growth factor-beta (TGF-beta) type I and type II receptors are both required for TGF-beta-mediated extracellular matrix production in lung fibroblasts. Mol. Cell Endocrinol. 150, 91–97.
Kim, S. J., Im, Y. H., Markowitz, S. D., and Bang, Y. J. (2000) Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev. 11, 159–168.
Hoosein, N., McKnight, M., Levine, A., et al. (1989) Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-b1. Exp. Cell Res. 181, 442–453.
Grady, W., Myeroff, L., Swinler, S., et al. (1999) Mutational inactivation of transforming growth factor b receptor type II in microsatellite stable colon cancers. Cancer Res. 59, 320–324.
Parsons, R., Myeroff, L., Liu, B., et al. (1995) Microsatellite instability and mutations of the transforming growth factor b type II receptor gene in colorectal cancer. Cancer Res. 55, 5548–5550.
Myeroff, L., Parsons, R., Kim, S.-J., et al. (1995) A transforming growth factor b receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55, 5545–5547.
Wang, J., Sun, L., Myeroff, L., et al. (1995) Demonstration that mutation of the type II transforming growth factor b receptor inactivates its tumor supressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270, 22044–22049.
Lu, S. L., Kawabata, M., Imamura, T., Miyazono, K., and Yuasa, Y. (1999) Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene. Biochem. Biophys. Res. Commun. 259, 385–390.
Lynch, H. and Smyrk, T. (1996) Hereditary nonpolyposis colorectal cancer (Lynch syndrome): an updated review. Cancer 78, 1149–1167.
Watanabe, T., Wu, T. T., Catalano, P. J., et al. (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344, 1196–1206.
Jarvinen, H. and Franssila, K. O. (1984) Familial juvenile polyposis coli; increased risk of colorectal cancer. Gut. 25, 792–800.
Fearon, E. R., Cho, K. R., Nigro, J. M., et al. (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49–56.
Takagi, Y., Kohmura, H., Futamura, M., et al. (1996) Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 111, 1369–1372.
Eppert, K., Scherer, S., Ozcelik, H., et al. (1996) MADR2 maps to 18q21 and encodes a TGFb-regulated MAD-related protein that is functionally mutated in colorectal cancer. Cell 86, 543–552.
Kretzschmar, M., Liu, F., Hata, A., Doody, J., and Massague, J. (1997) The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 11, 984–995.
Zhang, Y., Feng, X.-H., Wu, R.-Y., and Derynck, R. (1996) Receptor-associated Mad homologues synergize as effectors of the TGF-b response. Nature 383, 168–172.
Souchelnytskyi, S., Tamaki, K., Engstrom, U., Wernstedt, C., ten Dijke, P., and Heldin, C. H. (1997) Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J. Biol. Chem. 272, 28107–28115.
Abdollah, S., Macias-Silva, M., Tsukazaki, T., Hayashi, H., Attisano, L., and Wrana, J. L. (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 272, 27678–27685.
Chen, Y. G., Hata, A., Lo, R. S., Wotton, D., Shi, Y., Pavletich, N., and Massague, J. (1998) Determinants of specificity in TGF-beta signal transduction. Genes Dev. 12, 2144–2152.
Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L., and Wrana, J. L. (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95, 779–791.
Hata, A., Lo, R. S., Wotton, D., Lagna, G., and Massague, J. (1997) Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4 [see comments]. Nature 388, 82–87.
Liu, F., Pouponnot, C., and Massague, J. (1997) Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev. 11, 3157–3167.
de Caestecker, M., Piek, E., and Roberts, A. The role of TGF-b signaling in cancer. J. Natl. Cancer Instit., in press.
de Caestecker, M. P., Hemmati, P., Larisch-Bloch, S., Ajmera, R., Roberts, A. B., and Lech-leider, R. J. (1997) Characterization of functional domains within Smad4/DPC4. J. Biol. Chem. 272, 13690–13696.
Hocevar, B. A., Brown, T. L., and Howe, P. H. (1999) TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 18, 1345–1356.
Dai, J. L., Schutte, M., Bansal, R. K., Wilentz, R. E., Sugar, A. Y., and Kern, S. E. (1999) Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol. Carcinog. 26, 37–43.
Lagna, G., Hata, A., Hemmati-Brivanlou, A., and Massague, J. (1996) Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 383, 832–836.
Kim, S. J., Angel, P., Lafyatis, R., et al. (1990) Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol. Cell Biol. 10, 1492–1497.
Ashcroft, G. S., Yang, X., Glick, A. B., et al. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response [see comments]. Nat. Cell Biol. 1, 260–266.
Nagarajan, R. P., Zhang, J., Li, W., and Chen, Y. (1999) Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J. Biol. Chem. 274, 33412–33418.
von Gersdorff, G., Susztak, K., Rezvani, F., Bitzer, M., Liang, D., and Bottinger, E. P. (2000) Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. J. Biol. Chem. 275, 11320–11326.
Wong, C., Rougier-Chapman, E. M., Frederick, J. P., et al. (1999) Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta. Mol. Cell Biol. 19, 1821–1830.
Jonk, L. J., Itoh, S., Heldin, C. H., ten Dijke, P., and Kruijer, W. (1998) Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem. 273, 21145–21152.
Grau, A. M., Zhang, L., Wang, W., et al. (1997) Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res. 57, 3929–3934.
Datto, M. B., Hu, P. P., Kowalik, T. F., Yingling, J., and Wang, X. F. (1997) The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol. Cell Biol. 17, 2030–2037.
Li, J. M., Nichols, M. A., Chandrasekharan, S., Xiong, Y., and Wang, X. F. (1995) Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J. Biol. Chem. 270, 26750–26753.
Hahn, S., Schutte, M., Shamsul Hoque, A., et al. (1996) DPC4, a candidate tumor supressor gene at human chromosome 18q21.1. Science 271, 350–353.
Riggins, G., Thiagalingam, S., Rozenblum, E., et al. (1996) Mad-related genes in the human. Nat. Genet. 13, 347–349.
Takaku, K., Oshima, M., Miyoshi, H., Matsui, M., Seldin, M., and Taketo, M. (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92, 645–656.
Takaku, K., Miyoshi, H., Matsunaga, A., Oshima, M., Sasaki, N., and Taketo, M. M. (1999) Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 59, 6113–6117.
Xu, X., Brodie, S. G., Yang, X., et al. (2000) Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19, 1868–1874.
Friedl, W., Kruse, R., Uhlhaas, S., et al. (1999) Frequent 4-bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis patients. Genes Chromosomes Cancer 25, 403–406.
Roth, S., Sistonen, P., Salovaara, R., et al. (1999) A. SMAD genes in juvenile polyposis. Genes Chromosomes Cancer 26, 54–61.
Woodford-Richens, K., Williamson, J., Bevan, S., et al. (2000) Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium. Cancer Res. 60, 2477–2482.
Howe, J. R., Bair, J. L., Sayed, M. G., et al. (2001) Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet. 28, 184–187.
Kawabata, M., Imamura, T., and Miyazono, K. (1998) Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 9, 49–61.
Mishina, Y., Suzuki, A., Ueno, N., and Behringer, R. R. (1995) Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev. 9, 3027–3037.
Rowan, A., Bataille, V., MacKie, R., et al. (1999) Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. J. Invest. Dermatol. 112, 509–511.
Su, G. H., Hruban, R. H., Bansal, R. K., et al. (1999) Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 154, 1835–1840.
Wang, Z. J., Churchman, M., Campbell, I. G., et al. (1999) Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br. J. Cancer 80, 70–72.
Itzkowitz, S. and Kim, Y. (1998) Colonic polyps and polyposis syndromes, in: M. Feldman, B. Scharschmidt, and M. Sleisenger, eds., Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 6th ed., Saunders, Philadelphia, vol. 2, p. 1891.
Jenne, D. E., Reimann, H., Nezu, J., et al. (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18, 38–43.
Hemminki, A., Markie, D., Tomlinson, I., et al. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184–187.
Ylikorkala, A., Avizienyte, E., Tomlinson, I. P., et al. (1999) Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum. Mol. Genet. 8, 45–51.
Yoon, K. A., Ku, J. L., Choi, H. S., et al. (2000) Germline mutations of the STK11 gene in Korean Peutz-Jeghers syndrome patients. Br. J. Cancer 82, 1403–1406.
Westerman, A. M., Entius, M. M., Boor, P. P., et al. (1999) Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families. Hum. Mutat. 13, 476–481.
Smith, D. P., Spicer, J., Smith, A., Swift, S., and Ashworth, A. (1999) The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase. Hum. Mol. Genet. 8, 1479–1485.
Park, W. S., Moon, Y. W., Yang, Y. M., et al. (1998) Mutations of the STK11 gene in sporadic gastric carcinoma. Int. J. Oncol. 13, 601–604.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Grady, W.M., Markowitz, S.D. (2003). Hereditary Colon Cancer Genes. In: El-Deiry, W.S. (eds) Tumor Suppressor Genes. Methods in Molecular Biology™, vol 222. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-328-3:059
Download citation
DOI: https://doi.org/10.1385/1-59259-328-3:059
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-986-5
Online ISBN: 978-1-59259-328-6
eBook Packages: Springer Protocols